美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · BBIO近 30 天 17 則 · 第 1 / 1 頁
- BioMarin Stops Voxzogo Development for Noonan Syndrome
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
- BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
- Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
- BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis?
- How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
- Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
- BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
- What Does BridgeBio Pharma (BBIO) Gain From Its New US Drug Access Deal?
- Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
- 4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
- Mid-cap biotechs join Trump’s latest round of drug pricing deals
- Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
- BridgeBio (BBIO) Stock Looks Fully Priced Despite Fresh Acoramidis Data
- BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
- Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
- Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
- BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。